Manijeh Mahdavi - Applied Physiology Research Center, Cardiovascular research institute, Isfahan University of Medical Sciences, Isfahan, Iran
Majid Kheirollahi - Department of Genetics and Molecular Biology, School of Medicine, Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-communicable disease, Isfahan University of Medical Sciences, Isfahan, Iran
Violaine Moreau - CNRS UMR۵۰۴۸– UM- INSERM U۱۰۵۴, Centre de Biochimie Structurale, ۲۹, rue de Navacelles, ۳۴۰۹۰ Montpellier Cedex, France
Mehrnaz Keyhanfar - Isfahan university. Biotechnology department. Isfahan. Iran

The insulin-like growth factor-1 receptor (IGF-1R) plays a key role in proliferation, growth, differentiation, and development of several human malignancies including breast and pancreatic adenocarcinoma. IGF-1R targeted immunotherapeutic approaches are particularly attractive, as they may potentially elicit even stronger antitumor responses than traditional targeted approaches. Cancer peptide vaccines can produce immunologic responses against cancer cells by triggering helper T cell (Th) or cytotoxic T cells (CTL) in association with Major Histocompatibility Complex (MHC) class I or II molecules on the cell surface of antigen presenting cells. In our previous study, we set a technique based on molecular docking in order to find the best MHC class I and II binder peptides using GOLD. In the present work, molecular docking analysis on a library consisting of 30 discontinuous peptides from IGF-1R identified peptides 249 and 86, as the best MHC binder peptides to both MHC class I and II molecules used in the study. The most often targeted receptors for the peptide 249 were HLA-DR4, HLA-DR3 and HLA-DR2 and also for peptide 86, were HLA-DR4, HLA-DP2 and HLA-DR3. These findings, based on bioinformatics analyses, can be conducted in further experimental analyses in cancer therapy and vaccine design.

Docking, MHC, Bioinformatics, Peptide vaccine, IGF-1 receptor